US equities
|
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
TSLA
$407.46
▲+4.04%
NVDA
$217.94
▲+0.90%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
TSLA
$407.46
▲+4.04%
NVDA
$217.94
▲+0.90%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
43.96
+0.54 (+1.24%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
↗
October 21, 2026
This beaten-down biotech has a better story than its stock chart suggests.
Via
The Motley Fool
Alnylam vs. Ionis: Here's the Better Bad-News Buy
↗
October 10, 2026
The sell-offs for both of these beaten-down biotech stocks appear to be overdone.
Via
The Motley Fool
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
↗
September 28, 2026
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
Via
The Motley Fool
Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates
↗
July 29, 2026
Via
Chartmill
Topics
Earnings
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Surge After Crushing Q1 Estimates and Raising Full-Year Guidance
↗
April 29, 2026
Via
Chartmill
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
↗
September 20, 2026
Shares of Ionis are down more than 40% so far this year.
Via
The Motley Fool
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
↗
September 19, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while...
Via
MarketBeat
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
↗
September 14, 2026
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
Via
The Motley Fool
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
↗
September 09, 2026
Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks.
Via
The Motley Fool
Stay updated with the stocks that are on the move in today's after-hours session.
↗
September 04, 2026
Via
Chartmill
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
↗
September 04, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive...
Via
MarketBeat
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
↗
September 03, 2026
This biotech stock looks like a great candidate to buy on the admittedly steep dip.
Via
The Motley Fool
Breakfast News: A Conversation With Ionis CEO
↗
August 22, 2026
Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.
Via
The Motley Fool
Topics
ETFs
World Trade
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
↗
August 16, 2026
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
Via
The Motley Fool
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?
↗
August 14, 2026
A drug that didn't meet expectations in a trial is to blame.
Via
The Motley Fool
Ionis (IONS) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated.
Via
The Motley Fool
Topics
Earnings
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
↗
August 03, 2026
Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement.
Via
The Motley Fool
Topics
Regulatory Compliance
Ionis Pharmaceuticals Q2 Earnings Call Highlights
↗
July 29, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch...
Via
MarketBeat
Topics
Earnings
Cathie Wood Just Bet Big on This Biotech Stock
↗
July 18, 2026
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?
Via
The Motley Fool
Topics
ETFs
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
↗
July 13, 2026
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Via
MarketBeat
Which stocks are experiencing notable movement on Thursday?
↗
July 09, 2026
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
July 09, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
July 09, 2026
Via
Chartmill
Discover the top movers in Thursday's pre-market session.
↗
July 09, 2026
Via
Chartmill
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
↗
June 19, 2026
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....
Via
InvestorPlace
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
↗
May 31, 2026
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
Via
The Motley Fool
Topics
Regulatory Compliance
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
↗
May 25, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare...
Via
MarketBeat
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
↗
May 18, 2026
Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis...
Via
MarketBeat
Ionis (IONS) Q1 2026 Earnings Call Transcript
↗
April 29, 2026
Ionis (IONS) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Ionis (IONS) Q4 2025 Earnings Transcript
↗
April 21, 2026
Ionis (IONS) Q4 2025 Earnings Transcript
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
